- Pharma
- 1 min read
Chinese-owned Gland Pharma re-appoints Srinivas Sadu as MD & CEO
Gland Pharma reported revenues of Rs 3463 and a net profit of Rs 997 crore in FY21. Shares of Gland Pharma rose 1.89% to close at Rs 3360 on BSE on Thursday, the benchmark Sensex gained 1.50% to 55,464.39 points.
Read by
The company also nominated Yao Fang as additional director on the board.
Fang has been serving as co-chairman of the Board and executive director in Shanghai Fosun Pharmaceutical (Group) Co since June 8, 2016.
Fang will be replacing Dongming Li, who is co-president at Shanghai Fosun Pharmaceutical.
Shanghai Fosun Pharmaceutical (Group) acquired a 74 percent stake in Gland Pharma for about $1.1 billion in 2017. It bought the stake from US private equity investor KKR.
The company went through a successful IPO in November 2020. The Chinese company holds 58% stake in Gland Pharma.
Gland Pharma reported revenues of Rs 3463 and a net profit of Rs 997 crore in FY21.
Shares of Gland Pharma rose 1.89% to close at Rs 3360 on BSE on Thursday, the benchmark Sensex gained 1.50% to 55,464.39 points.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions